PET/CT Findings in Testicular Cancer
Positron emission tomography (PET), in combination with computed tomography (CT), (PET/CT) has been used in the last decade in germ cell testicular cancer, tackling conventional imaging shortcomings and diagnostic controversies, such as accurate initial staging of early-stage patients, post-chemotherapy residual mass characterization, workup of patients with rising tumor markers and negative or equivocal conventional imaging and predicting response to treatment.
- 3.Vela A, Deslandes E, Vera P et al (1999) The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 83:649–653Google Scholar
- 7.Huddart RA, O’Doherty MJ, Padhani A et al (2007) 18 fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC trial TE22–the NCRI testis tumour clinical study group. J Clin Oncol 25:3090–3095CrossRefGoogle Scholar
- 13.Treglia G, Sadeghi R, Annunziata S et al (2014) Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis. Biomed Res Int. Article ID 852681Google Scholar
- 15.Necchi A, Nicolai N, Alessi A et al (2016) Interim (18)F-fluorodeoxyglucose positron emission tomography for early metabolic assessment of response to cisplatin, etoposide, and bleomycin chemotherapy for metastatic seminoma: clinical value and future directions. Clin Genitourin Cancer 14:249–254CrossRefGoogle Scholar
- 20.Kollmannsberger C, Oechsle K, Dohmen B et al (2002) Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumour markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94:2353–2362CrossRefGoogle Scholar